Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Metastatic Melanoma

出处
期刊:Oncology times [Wolters Kluwer]
卷期号:43 (18): 30-30
标识
DOI:10.1097/01.cot.0000793212.53236.0c
摘要

Metastatic Melanoma: Metastatic MelanomaPatients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as well to an investigational therapy that involves the adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) as those patients who were naïve to these treatments, according to results of a study published in Clinical Cancer Research (2021; doi: 10.1158/1078-0432.CCR-21-1171). Recent treatment options for patients with metastatic melanoma include immunotherapies such as anti-PD-1/PD-L1 antibodies or molecularly targeted therapies such as inhibitors of BRAF and/or MEK, components of the MAPK pathway. Many patients eventually develop resistance to these therapies, however, and seek other options, such as ACT-TIL. “We noticed, over the last few years, we were seeing fewer responses to ACT-TIL in metastatic melanoma patients, which coincided with these newer therapies coming on board,” said Stephanie Goff, MD, an associate research physician in the Surgery Branch of the National Cancer Institute of the National Institutes of Health. “We wanted to see if there were differences in responses between those who had received prior immunotherapy or targeted therapies and those who did not. “The data in this manuscript demonstrate that if you wait to use ACT-TIL as a later-line therapy, you may not get the same durable responses as when you use it up front,” she said. “We should think about utilizing TILs earlier in the disease course.” Study Details Goff and colleagues studied the outcomes of 226 patients from four completed ACT-TIL clinical trials, 83 percent of whom had disease that relapsed on a prior therapy. They examined differences in response based on characteristics such as age, sex, tumor size and location, and prior treatments. While age and sex had no effect on outcome, elevated lactate dehydrogenase, a prognostic indicator for melanoma, or a larger baseline tumor were associated with poorer prognosis. The objective response rate was 56 percent among patients who had never received anti-PD-1 therapy (but may have received other therapies), which fell to 24 percent among patients who had received prior anti-PD-1 therapy. In patients who received prior MAPK inhibitors, objective response rate was 21 percent, compared to 60 percent in MAPK inhibitor-naïve patients. Similarly, the median progression-free survival was 6.5 months among patients who had never received anti-PD-1 therapy, which fell to 3.2 months among patients who had received prior anti-PD-1 therapy. In patients who received prior MAPK inhibitors, median progression-free survival was 2.5 months, compared to 6.6 months in MAPK inhibitor-naïve patients. In order to perform ACT-TIL, investigators harvest lymphocytes from a tumor sample, induce them to proliferate outside of the body, and return them to the patient to help eliminate the tumor. Tumors exposed to prior treatments may pose some hurdles, including yielding fewer or less robust lymphocytes for the ACT-TIL to be effective, Goff explained. She noted these data present an argument for harvesting treatment-naïve lymphocytes before a patient tries other therapies, so that ACT-TIL is available if the patient relapses. “If we harvest the lymphocytes before they've seen any medications, we could potentially develop it into an effective later-line therapy with better response rates,” she said. Limitations of this study include the large window of time (2000-2020) in which these trials were performed, which creates a discrepancy in screening and care systems between patients treated earlier versus later in that window. Additionally, overall and melanoma-specific survival statistics may be skewed by the treatments patients received following ACT-TIL, which the authors were unable to track in patients who developed progressive disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
桐桐的应助被健康的魔镜采纳,获得10
1秒前
绿地土狗完成签到,获得积分10
1秒前
ding的应助被nikola采纳,获得10
2秒前
科研通AI6.4的应助被筑梦之鱼采纳,获得10
2秒前
wxwx发布了新的文献求助10
3秒前
加油完成签到 ,获得积分10
5秒前
5秒前
6秒前
6秒前
8秒前
qiqi发布了新的文献求助10
9秒前
9秒前
wanci的应助被小小怪采纳,获得10
9秒前
wangbw发布了新的文献求助10
9秒前
10秒前
Pupupapa完成签到,获得积分20
10秒前
lulu完成签到,获得积分10
11秒前
Bai发布了新的文献求助10
11秒前
Akim的应助被blinkals57采纳,获得10
11秒前
ui24发布了新的文献求助10
11秒前
11秒前
淡定访琴完成签到,获得积分10
12秒前
搜集达人的应助被mhx1234567890采纳,获得10
13秒前
15秒前
孤独的凤完成签到,获得积分10
15秒前
16秒前
16秒前
音阙发布了新的文献求助10
16秒前
Sxya发布了新的文献求助30
17秒前
dingyushu完成签到,获得积分10
17秒前
秋风的应助被pinkstar采纳,获得10
17秒前
科研通AI6.3的应助被向星采纳,获得10
18秒前
18秒前
18秒前
dkfsgeicn完成签到,获得积分10
19秒前
情怀的应助被ZYH采纳,获得10
19秒前
20秒前
orixero的应助被Kevin采纳,获得10
20秒前
phoebe发布了新的文献求助10
21秒前
研友_VZG7GZ的应助被香辣牛排采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593